Medivation Inc (MDVN)

MDVN (NASDAQ:Drugs)
$99.17
pos +1.27
+1.30%
Today's Range: 97.45 - 100.92 | MDVN Avg Daily Volume: 1,174,500
Last Update: 10/23/14 - 3:11 PM EDT
Volume: 500,104
YTD Performance: 53.40%
Open: $98.59
Previous Close: $97.90
52 Week Range: $53.65 - $103.88
Oustanding Shares: 76,788,933
Market Cap: 7,446,222,833
6-Month Chart
TheStreet Ratings Grade for MDVN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 12 10 10
Moderate Buy 0 0 0 0
Hold 2 2 4 4
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 1.57 1.53 1.80 1.80
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 334.38
Price Earnings Comparisons:
MDVN Sector Avg. S&P 500
334.38 349.90 28.03
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
30.69% 81.67% 1,013.13%
GROWTH 12 Mo 3 Yr CAGR
Revenue 50.20 3.37 0.63
Net Income 0.00 0.25 0.00
EPS 0.00 0.14 0.00
Earnings for MDVN:
EBITDA -0.02B
Revenue 0.27B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $1.04 $1.06 $2.49 $3.44
Number of Analysts 8 8 9 8
High Estimate $1.48 $1.82 $3.30 $4.67
Low Estimate $0.87 $0.54 $1.94 $1.83
Prior Year $-0.18 $0.03 $-0.57 $2.49
Growth Rate (Year over Year) 679.17% 3,416.67% 536.06% 38.35%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bearishMedivation downgraded at Goldman

Sep 24, 2014 | 6:45 AM EDT

MDVN was downgraded from Buy to Neutral, Goldman Sachs said. Valuation call, based on a $110 price target.

bullishMedivation upgraded at Canaccord

Sep 18, 2014 | 7:20 AM EDT

MDVN was upgraded to Buy, Canaccord Genuity said. $132 price target. Company is gaining market share in the pre-chemotherapy market. 

By

Dick Arms

 | Sep 16, 2014 | 7:15 AM EDT

Consider going short if you aren't already.

bullishMedivation upgraded at Bernstein

Sep 9, 2014 | 8:12 AM EDT

MDVN was upgraded from Market Perform to Outperform, Bernstein said. $118 price target. Prevail should drive growth. 

bearishMedivation price target, EPS cut at UBS

Mar 3, 2014 | 7:49 AM EST

MDVN lowered its numbers, UBS said. Driven by disappointing Xtandi guidance. $85 price target and Buy rating, 

bearishMedivation downgraded at Needham

Feb 3, 2014 | 7:36 AM EST

MDVN was downgraded from Buy to Hold, Needham said. Valuation call. 

 

bullishMedivation price target, EPS lifted at UBS

Jan 29, 2014 | 7:31 AM EST

MDVN raised its price target and estimates through 2015, UBS said. Better-than-expected full PREVAIL data, appearing favorably vs Zytiga on a cross-trial comparison basis. $93 price target and Buy rating. 

bullishMedivation upgraded at UBS

Jul 17, 2013 | 7:57 AM EDT

MDVN was upgraded to Buy from Neutral and given a $74 price target, said UBS. The upgrade comes ahead of the ph3 PREVAIL study.

bullishMedivation rated new Buy at Needham

Mar 4, 2013 | 7:09 AM EST

MDVN was initiated with a Buy rating, Needham said. Xtandi is rapidly gaiing market share for the treatment of prostate cancer.

 

updateMedivation rated new Neutral at UBS

Dec 19, 2012 | 8:44 AM EST

MDVN was initiated with a Neutral rating, UBS said. $59 price target. Xtandi should drive conversion to profitability, but peak expectations high. 

Take the money and run! I greatly appreciate Howard's input and find it both accurate and ...
I used the big drop following Boulder Brands (BDBD) earnings report to close out my 'Best ...
Tim C., GDXJ certainly ranks high in the "buy low" department, but I think that's about it...
While Google (GOOG) has moved in sympathy with the overall market's "V" recovery rally off...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.